| May-16-22 08:00AM |
Entera Bio Board Member, Miranda Toledano, to Assume Role of Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy |
GlobeNewswire |
| May-12-22 08:00AM |
Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights |
GlobeNewswire |
| May-05-22 08:00AM |
Entera Bio Files Patent Applications for Inventions that Optimize its Platform Technology for Oral Delivery of Large Molecule Therapeutics |
GlobeNewswire |
| Apr-28-22 08:00AM |
Entera Bio to Report First Quarter 2022 Financial Results on May 12 |
GlobeNewswire |
| Apr-08-22 05:02PM |
Recession Fears are Creating a Golden Opportunity for Biotech Stocks |
InvestorPlace |
| Mar-22-22 08:00AM |
Entera Bio to Present at 2022 Maxim Virtual Growth Conference |
GlobeNewswire |
| Mar-16-22 06:14AM |
Companies Like Entera Bio (NASDAQ:ENTX) Are In A Position To Invest In Growth |
Simply Wall St. |
| Mar-08-22 06:30AM |
Entera Bio Reports Financial Results for the Year Ended December 31, 2021 |
GlobeNewswire |
| Mar-03-22 09:50AM |
Entera Bio to Report Business and Financial Results for the Year Ended December 31, 2021 on March 8, 2022 |
GlobeNewswire |
| Feb-17-22 08:30AM |
Entera Bio to Present at Aegis Virtual Conference on February 23rd |
GlobeNewswire |
| Jan-04-22 08:30AM |
Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (bone mineral density) as the Primary Endpoint |
GlobeNewswire |
| Nov-10-21 08:30AM |
Entera Bio Reports Third Quarter 2021 Financial Results |
GlobeNewswire |
| Oct-28-21 08:30AM |
Entera Bio Publishes Key Study Describing its Oral Delivery Technology Platform for Biologic Drugs |
GlobeNewswire |
| Oct-06-21 03:47PM |
Entera Bio's Formulated Human Parathyroid Hormone Shows Encouraging BMD Data |
Benzinga |
| Oct-06-21 08:30AM |
Entera Bio Presents Positive Phase 2 6-Month Bone Mineral Density Data for Oral PTH Formulation at Late Breaker ASBMR Conference Session |
GlobeNewswire |
| Sep-17-21 08:09AM |
Entera Bio (NASDAQ:ENTX) Is In A Strong Position To Grow Its Business |
Simply Wall St. |
| Sep-01-21 08:30AM |
Entera Bio Selected for Late Breaking Oral Presentation of Phase 2 6-Month Osteoporosis Data at ASBMR 2021 Annual Meeting |
GlobeNewswire |
| Aug-23-21 11:00AM |
Entera Bio to Conduct Annual Shareholders Meeting on October 4, 2021 |
GlobeNewswire |
| Aug-23-21 08:30AM |
Entera Bio to Present at H.C. Wainwright 23rd Annual Global Investment Conference |
GlobeNewswire |
| Aug-19-21 09:04AM |
New Strong Sell Stocks for August 19th |
Zacks |
| Aug-16-21 06:30AM |
Entera Bio Reports Second Quarter 2021 Financial Results and Provides Clinical Updates |
GlobeNewswire |
| Aug-13-21 04:30PM |
Entera Bio to Report Business and Financial Results for the Quarter ended June 30, 2021, on August 16, 2021 |
GlobeNewswire |
| Aug-06-21 10:20AM |
10 Biotech Penny Stocks to Buy According to Reddit |
Insider Monkey |
| Aug-02-21 08:30AM |
Entera Bio to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment 3-Month Findings at the American Society for Bone and Mineral Research Annual Meeting |
GlobeNewswire |
| Jun-28-21 03:15PM |
Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613 Positioned to be the First Oral Bone-Building Agent for the Treatment of Osteoporosis |
GlobeNewswire |
| Jun-25-21 06:23PM |
Entera Bio Stock Could More Than Double From Here, Says Analyst |
TipRanks |
| Jun-24-21 12:38PM |
Entera (ENTX) Up on Positive Results From Osteoporosis Drug |
Zacks |
| Jun-24-21 03:33AM |
Entera Bio Surging on Drug Development; Will the Rise Continue? |
TipRanks |
| Jun-23-21 08:30AM |
Entera Bio Announces Excellent Topline Phase 2 BMD Data for EB613, the Study Met Its Primary and Key Secondary Endpoints |
GlobeNewswire |
| Jun-23-21 07:39AM |
Entera Bio Soars on Phase 2 Progress With Osteoporosis Treatment |
TheStreet.com |
| Jun-19-21 05:12AM |
Are Institutions Heavily Invested In Entera Bio Ltd.'s (NASDAQ:ENTX) Shares? |
Simply Wall St. |
| Jun-18-21 06:22AM |
Entera Bio (ENTX) is Overbought: Is A Drop Coming? |
Zacks |
| Jun-17-21 08:00AM |
Entera Bio Receives Foundational Patent for its Oral PTH using its Platform Oral Protein Delivery Technology in European Union |
GlobeNewswire |
| May-20-21 08:00AM |
Entera Bio Reports First Quarter 2021 Financial Results and Provides Clinical Updates |
GlobeNewswire |
| May-19-21 08:47AM |
Here's Why Entera Bio (ENTX) Stock Has Almost Tripled This Year |
Zacks |
| May-19-21 06:42AM |
The Zacks Analyst Blog Highlights: BioNTech, Ocugen, Rubius Therapeutics and Entera Bio |
Zacks |
| May-18-21 09:06AM |
4 Biotech Stocks That Have Already Doubled This Year So Far |
Zacks |
| Apr-20-21 08:45AM |
Entera Announces Ron Mayron, a Global Pharma Leader, Joins its Board of Directors |
GlobeNewswire |
| Apr-15-21 08:30AM |
Entera Appoints Ramesh Ratan as Chief Financial Officer |
GlobeNewswire |
| Apr-06-21 08:30AM |
New Data Suggest Enteras Platform Orally Delivers Human Growth Hormone, Study Results to be Presented at European Pharma Congress |
GlobeNewswire |
| Mar-25-21 07:30AM |
Abeona Therapeutics Announces Appointment of Two New Independent Members to its Board of Directors |
GlobeNewswire |
| Mar-18-21 08:00AM |
Entera Bio Ltd Announces Operating and Financial Results for the Fourth Quarter and Year Ended December 31, 2020 |
GlobeNewswire |
| Mar-18-21 06:30AM |
Entera Bio Ltd. to Host Earnings Call |
ACCESSWIRE |
| Mar-14-21 08:14AM |
Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations |
Benzinga |
| Mar-12-21 07:36AM |
The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs |
Benzinga |
| Mar-11-21 04:15PM |
Entera Bio to Report Financial Results for the Year Ended December 31, 2020 on March 18, 2021 |
GlobeNewswire |
| Mar-11-21 09:23AM |
Entera Bio Stock Skyrockets On Positive EB613 Biomarker Analysis Data In Osteoporosis Study |
Benzinga |
| Mar-11-21 08:30AM |
Entera Bio Ltd Announces Positive Topline EB613 Phase 2 Biomarker Data |
GlobeNewswire |
| Mar-04-21 08:30AM |
Entera Bio To Present At The H.C. Wainwright Global Life Sciences Conference |
GlobeNewswire |
| Feb-25-21 08:30AM |
Entera Bio Announces Publication of Phase 2 Hypoparathyroidism Study in the Journal of Bone and Mineral Research |
GlobeNewswire |
| Feb-20-21 03:00AM |
We're A Little Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Rate |
Simply Wall St. |
| Feb-08-21 08:30AM |
Entera Bio Initiates New Research Program For Oral GLP-2 |
GlobeNewswire |
| Jan-11-21 08:30AM |
Entera Bio Issues Letter to Shareholders |
GlobeNewswire |
| Dec-10-20 08:30AM |
Entera Bio Announces FDA Approval of IND Application for EB613 an Oral Human Parathyroid Hormone (1-34) for the Treatment of Osteoporosis |
GlobeNewswire |
| Dec-01-20 08:08AM |
The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit |
Benzinga |
| Nov-30-20 04:05PM |
Entera Bio Appoints Spiros Jamas as Chief Executive Officer |
GlobeNewswire |
| Nov-19-20 06:45AM |
Entera Bio Ltd. to Host Earnings Call |
ACCESSWIRE |
| Nov-19-20 06:30AM |
Entera Bio Ltd Announces Third Quarter 2020 Financial Results and Provides Clinical Update |
GlobeNewswire |
| Nov-13-20 07:30AM |
Entera Bio to Report Third Quarter 2020 Business and Financial Results on November 19, 2020 |
GlobeNewswire |
| Nov-09-20 08:30AM |
Entera Bio Ltd Announces Completion of Enrollment In Phase 2 Clinical Trial of Eb613 In Osteoporosis |
GlobeNewswire |
| Nov-02-20 04:05PM |
Entera Bio to Present at the H.C. Wainwright 6th Annual Israel Conference |
GlobeNewswire |
| Sep-10-20 08:30AM |
Entera Bio to Present at the H.C. Wainwright 22nd Annual Global Investment Conference |
GlobeNewswire |
| Aug-24-20 10:19AM |
Here's Why We're Watching Entera Bio's (NASDAQ:ENTX) Cash Burn Situation |
Simply Wall St. |
| Aug-20-20 08:00AM |
The Daily Biotech Pulse: CureVac Close To Coronavirus Vaccine Deal With EU, Entera Bio's Positive Readout, Patent Protection For Co-Diagnostics |
Benzinga |
| Aug-20-20 06:30AM |
Entera Bio Ltd Announces Interim Data From Phase 2 Clinical Trial of EB613 in Osteoporosis and Second Quarter 2020 Financial Results |
GlobeNewswire |
| Aug-17-20 08:30AM |
Entera Bio to Report Second Quarter 2020 Business and Financial Results on August 20, 2020 |
GlobeNewswire |
| Aug-10-20 08:30AM |
Entera Bio Announces Management Changes |
GlobeNewswire |
| Aug-05-20 08:30AM |
Entera Bio to Present at BTIGs Virtual Biotechnology Conference |
GlobeNewswire |
| Jul-23-20 08:25AM |
The Daily Biotech Pulse: Midatech Shelves Sale Plan, G1 Therapeutics Out-Licenses, Entera Bio Jumps On Survey Results |
Benzinga |
| Jul-22-20 04:05PM |
Entera Bio Ltd. Announces Highly Encouraging Oral PTH Market Survey Results |
GlobeNewswire |
| Jul-07-20 08:30AM |
Entera Bio Ltd Provides Update on Phase 2 Clinical Trial of EB613 in Postmenopausal Women With Osteoporosis |
GlobeNewswire |
| May-21-20 06:30AM |
Entera Bio Ltd Announces Interim Biomarker Data From Phase 2 Clinical Trial of EB613 and First Quarter 2020 Financial Results |
GlobeNewswire |
| May-17-20 12:30PM |
The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Earnings Flow Slows |
Benzinga |
| May-07-20 08:30AM |
Entera Bio to Report Interim Data From EB613 Phase 2 Trial and First Quarter 2020 Business and Financial Results on May 21, 2020 |
GlobeNewswire |
| Mar-26-20 06:30AM |
ENTERA BIO LTD ANNOUNCES FINANCIAL AND OPERATING RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2019 |
GlobeNewswire |
| Mar-26-20 06:30AM |
Entera Bio Ltd. to Host Earnings Call |
ACCESSWIRE |
| Mar-16-20 04:15PM |
ENTERA BIO TO REPORT 2019 BUSINESS AND FINANCIAL RESULTS ON MARCH 26, 2020 |
GlobeNewswire |
| Feb-04-20 07:30AM |
Frost & Sullivan Releases Osteoporosis Drug Market Data |
PR Newswire |
| Dec-18-19 04:30PM |
Entera Bio Announces the Completion of $14.3 million Private Placement |
GlobeNewswire |
| Dec-11-19 05:00PM |
Entera Announces Closing of Private Placement |
GlobeNewswire |
| Nov-21-19 07:00AM |
Entera Bio Reports Third Quarter 2019 Financial Results and Provides Operating Update |
GlobeNewswire |
| Nov-21-19 07:00AM |
Entera Bio Establishes U.S. Headquarters and Announces Jonathan Lieber as Chief Financial Officer |
GlobeNewswire |
| Nov-18-19 08:37AM |
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate |
Simply Wall St. |
| Nov-07-19 04:30PM |
Entera Bio to Announce Third Quarter 2019 Financial Results on Thursday, November 21, 2019 |
GlobeNewswire |
| Oct-07-19 08:00AM |
Introducing Investors to Breakthrough Hi-tech and Bio-tech Companies: Frost & Sullivan Publishes Q2 Coverage for Investors to Make Informed Decisions |
PR Newswire |
| Sep-23-19 08:00AM |
Entera Bio Reports Positive Results from a Phase 2 PK/PD Study of Oral PTH (1-34) in Patients with Hypoparathyroidism |
GlobeNewswire |
| Sep-19-19 11:36AM |
Such Is Life: How Entera Bio (NASDAQ:ENTX) Shareholders Saw Their Shares Drop 51% |
Simply Wall St. |
| Sep-19-19 08:00AM |
Entera Bio to Present at the Ladenburg Thalmann 2019 Healthcare Conference |
GlobeNewswire |
| Aug-20-19 07:00AM |
Entera Bio Reports Second Quarter 2019 Financial Results and Provides Operating Update |
GlobeNewswire |
| Aug-20-19 06:30AM |
Entera Bio Ltd. to Host Earnings Call |
ACCESSWIRE |
| Aug-15-19 07:00AM |
Entera Bio to Announce Second Quarter and Six Months ended June 30, 2019 Financial Results on Tuesday, August 20, 2019 |
GlobeNewswire |
| Aug-05-19 08:00AM |
Entera Bio Appoints Adam Gridley as Chief Executive Officer |
GlobeNewswire |
| Jul-11-19 12:23PM |
What Type Of Shareholder Owns Entera Bio Ltd.'s (NASDAQ:ENTX)? |
Simply Wall St. |
| Jul-02-19 07:00AM |
Entera Announces Initiation of Phase 2 Dose Ranging Study for Oral PTH |
GlobeNewswire |
| Jul-01-19 08:00AM |
From Injections to Pills - Entera Bio (ENTX): Initiation of Coverage by Frost & Sullivan |
PR Newswire |
| Jun-27-19 07:00AM |
Entera Bio Reports First Quarter 2019 Financial Results and Operating Update |
GlobeNewswire |
| Mar-28-19 07:00AM |
Entera Bio Reports 2018 Annual Financial Results and Operating Update |
GlobeNewswire |
| Mar-28-19 07:00AM |
Entera Bio Announces 20-F Filing |
GlobeNewswire |
| Mar-27-19 11:02AM |
Entera Bio to Announce Fourth Quarter and Year Ended December 31, 2018 Financial Results on Thursday, March 28 |
GlobeNewswire |
| Mar-07-19 07:00AM |
Entera Bio Announces a Transition in the Chief Financial Officer Position |
GlobeNewswire |